CPT vs SRPT · P/E 104, rev $7.1M vs rev $1.90B
Camden Property Trust (CPT) versus Sarepta Therapeutics Inc (SRPT) — a side-by-side from cached financials, not a winner call.
Camden Property Trust (CPT) is a reit - residential company listed on US.
Sarepta Therapeutics Inc (SRPT) is a biotechnology company listed on US.
Latest reported CPT revenue for 2024-12-31 was $7.1M. Net income was $170.8M. Revenue was up 106.8% from 2023-12-31 to 2024-12-31. CPT currently screens at market cap $12.11B and trailing P/E 104.0.
Latest reported SRPT revenue for 2024-12-31 was $1.90B. Net income was $235.2M. Revenue was up 53.0% from 2023-12-31 to 2024-12-31. SRPT currently screens at market cap $2.34B.
CPT currently screens at market cap $12.11B and trailing P/E 104.0. SRPT currently screens at market cap $2.34B.
Not investment advice. Open the CPT and SRPT stock pages for the full models.
Not investment advice.